# Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy

> **NCT03993249** · PHASE2 · UNKNOWN · sponsor: **Hellenic GenitoUrinary Cancer Group** · enrollment: 78 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **BIOLOGICAL:** Nivolumab
- **OTHER:** chemoradiotherapy

## Key facts

- **NCT ID:** NCT03993249
- **Lead sponsor:** Hellenic GenitoUrinary Cancer Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-28
- **Primary completion:** 2022-08
- **Final completion:** 2023-12
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2022-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03993249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03993249, "Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03993249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*